1 reason to buy surgery after 70% of the surge and 5 reasons for passing News ad

Surgery NASDAQ: SURG Promotions grew by more than 70% after he released a solid leadership. This is the only reason for the purchase. The company expects that Q1 and, perhaps, the results of Q2 will be soft, agreeing with the 4th quarter of 2024, but after many years of effort, the income will begin to bloom in the rear half, and the cash flow will become positive. The forecast is intended at least 225% of annual growth and can be careful.

The company provides numerous telecommunication services and telecommunications services, including At & T. The integration of Surgepays products into the AT&T network is completed and will have a central place in the company’s results in 2025 and in the future.

These are the reasons why now there may be a good time to sell.

#1 – the price of shares has reached significant technical resistance

No matter how optimistic the rise in prices for shares can be, the price action reaches a solid roof of resistance and, perhaps, will not be able to rise higher. The ceiling is $ 2.60 and is aligned with the peak of the price and the ceiling set at the end of 2024. The resulting candle is also significant, since it formed a large and significant doji with a large volume, which is at risk of becoming an abandoned child.

An abandoned child-horsepower signal about the market, which is the result of a sharp bull movement, followed by a rapid retreat. In this case, the candle after the initial 70% of the surge is aligned with an abandoned children’s script and sets this market to continue the retreat.

#2 – Brief interest is not in the game … while

It is unlikely that a short coating, with a short percentage of 2.55%, had anything to do with an increase in prices for shares by 70%, but this is not necessary. The average daily volume, ahead of the report on the end of the year, was about 35,000, which is significantly lower than the fluid level, so loading of traffic caused by management had an excessively significant effect.

The volume per day of release approached 70 million shares during open trade, increasing by 200,000%, which is sufficient to absorb any shares available for purchase at any proposed price. The volume the day after the surge was higher than the average, but very low compared to 70 million. To date, today it is that with the price action at such high levels and a demonstration of resistance at a critical level, a short percentage is likely to grow and present a counter wind for the market in the second quarter of 2025.

#3 – analysts do not care about this action

Regardless of the prospects of income, positive cash flow and long -term financial health, analysts do not care about this action.

Marketbeat tracks only one analyst with a rating of less than 12 months, and it was supplied with a decrease in the target price at the end of 2024.

The device is a purchase, but it does not matter much when no one agrees.

Similarly, the purchase rating belongs to a small and relatively unknown company Ascentiant Capital Markets, so it has a low weight.

This lack of wider coverage may not give institutional and retail investors indecisive.

#4 – institutions do not care about this action

Institutional activity is technically optimistic, with the purchase of volume to get ahead of the volume of the dollar, but this means little. Institutions are owned by less than 8% of this action, and the activity of the 1st quarter is cool at best. Despite the fact that they can continue to buy in equilibrium, this will require a significant increase in pace and a decrease in generally affordable shares to increase the price of shares.

The likely scenario is that the institutions sold on the adhesion to make a profit and can wait for a rollback to buy more shares.

#5 – Hurgepays are well capitalized, but it has a deep hole to dig

Surgepays balance emphasizes its strong financial basis and the ability to continue work, but details are not all guilt and roses. The main points include a significant decrease in liability compensation by reducing funds and assets, a significant increase in deficiency and increasing the share.

The number of shares increased by 35% in F2024, which was a nanosa in the market. The price of Surgepays shares can increase with these factors, while others described in the game, but it will be a struggle, and the ratio of risk to unfavorable remuneration.

Before considering surgery services, you will want to hear it.

Marketbeat monitors the highest and most effective analysts with the most effective Wall Street analysts and promotions that they recommend to their customers daily. Marketbeat has identified five shares that leading analysts quietly whisper to their customers to buy now before the wider market is won … and Surgepays was not on the list.

While Surgepays currently has a purchase rating among analysts, analysts engaged in a high -ranking rating believe that these five promotions are better buying.

View five shares here

Like this article? Share this with a colleague.

The link is copied to the exchange buffer.